Ricevi le ultime notizie sulle azioni Krystal Biotech con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di KRYS

Ultime notizie per

KRYSTAL BIOTECH INC

Krystal Biotech

Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.

Krystal Biotech Inc

News

Press Releases

Krystal Biotech to Present at Goldman Sachs 46th Annual Global Healthcare Conference

General

Krystal Biotech Announces First Patient Dosed in Phase 3 Clinical Trial of KB803 for the Treatment and Prevention of Corneal Abrasions in Patients with Dystrophic Epidermolysis Bullosa

Krystal Biotech Announces First Patient Dosed in Phase 1/2 Trial of KB801 for the Treatment of Neurotrophic Keratitis

Health Care

Jeune Announces Positive Results and Significant Aesthetic Improvements from Phase 1 Study of KB304 for Moderate to Severe Wrinkles of the Décolleté

Krystal Biotech Announces Approval of VYJUVEK® by Japan's Ministry of Health, Labour and Welfare for the Treatment of Dystrophic Epidermolysis Bullosa

Krystal Biotech to Report Second Quarter 2025 Financial Results on August 4, 2025

Earnings

Krystal Biotech Announces Second Quarter 2025 Financial and Operating Results

Krystal Biotech Announces Update on Development Plans for Oncology Program KB707 and Prioritization of Inhaled KB707 for the Treatment of Non-Small Cell Lung Cancer

Krystal Biotech to Present at Cantor Global Healthcare Conference 2025

Krystal Biotech Announces FDA Approval of Updated VYJUVEK® Label

KRYS

Arcellx

ADMA Biologics

Akero Therapeutics

Alkermes

Apogee Therapeutics

Arrowhead Pharmaceuticals, Inc. - Common Stock

Arrowhead Pharma

CRISPR Therapeutics

Cytokinetics, Incorporated - Common Stock

Cytokinetics

Grifols, S.A. - American Depositary Shares

Grifols

Kymera Therapeutics

Legend Biotech Corporation - American Depositary Shares

Legend Biotech

Jyong Biotech

Mirum Pharmaceuticals, Inc. - common stock

Mirum Pharmaceuticals

Merus

Metsera

NewAmsterdam Pharma Company N.V. - Ordinary Shares

NewAmsterdam Pharma Co

Nuvalent

Vaxcyte

PTC Therapeutics

Protagonist Therapeutics, Inc. - Common Stock

Protagonist Therapeutics

uniQure

Rhythm Pharmaceuticals, Inc. - Common Stock

Rhythm Pharmaceuticals

Scholar Rock Holding Corporation - Common Stock

Scholar Rock Holding

TG Therapeutics

Viking Therapeutics

HC Wainwright & Co.

Chardan Capital

Citigroup

B of A Securities

Comments

Krystal Biotech Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO